Antibodies against type I IFN: The bad guys self-restrain in systemic lupus erythematosus.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

4 citing papers in PubMed, 5 citations in OpenAlex.

1. The emerging clinical relevance of cell-free DNA in lupus: from mechanistic insights to therapeutic opportunities.Frontiers in immunology · 2026
   Review
2. Successful splenectomy for refractory systemic lupus erythematosus-associated autoimmune hemolytic anemia: a case report and mechanistic insight.Frontiers in immunology · 2026
   Article
3. The role of autoantibodies in bridging obesity, aging, and immunosenescence.Immunity & ageing : I & A · 2024
   Review
4. [Research progress in systemic lupus erythematosus from 2021 to 2022].Zhongguo dang dai er ke za zhi = Chinese journal of contemporary pediatrics · 2023
   Review

Corrections and comments

• Comment on
  Inactive disease in patients with lupus is linked to autoantibodies to type I interferons that normalize blood IFNα and B cell subsets.2023

Authors and funding

1 author at 1 institution in 1 country.

Funding

No grant is acknowledged in the PubMed record.

Abstract

Indexed as